Showing results (1-10 of 16) with videos related to
Sort By:
Pageof 2
CPT: Pharmacometrics & Systems Pharmacology|January 29, 2026
Population Physiologically-Based Pharmacokinetic Modeling to Determine Ontogeny: A Quantitative Clinical Pharmacology Example in Pediatric Rare DiseaseYumi Cleary, Bhagwat Prasad, Kayode Ogungbenro, et al.Drug Metabolism and Disposition: the Biological Fate of Chemicals|December 23, 2021
Accelerating Clinical Development of Idasanutlin through a Physiologically Based Pharmacokinetic Modeling Risk Assessment for CYP450 Isoenzyme-Related Drug-Drug InteractionsKenichi Umehara, Yumi Cleary, Stephen Fowler, et al.The AAPS Journal|April 29, 2025
Simultaneous Estimation of fm and FG Values Directly from Clinical Drug-Drug Interaction Study DataYumi Cleary, Nicolo Milani, Kayode Ogungbenro, et al.British Journal of Clinical Pharmacology|September 11, 2018
Development of a physiologically based pharmacokinetic model for mefloquine and its application alongside a clinical effectiveness model to select an optimal dose for prevention of malaria in young Caucasian childrenTrevor N Johnson, Yumi Cleary, Neil Parrott, et al.The Journal of Pharmacology and Experimental Therapeutics|November 9, 2016
Low Potential of Basimglurant to Be Involved in Drug-Drug Interactions: Influence of Non-Michaelis-Menten P450 Kinetics on Fraction MetabolizedStephen Fowler, Elena Guerini, NaHong Qiu, et al.Current Pharmacology Reports|March 7, 2017
Progress in Prediction and Interpretation of Clinically Relevant Metabolic Drug-Drug Interactions: a Minireview Illustrating Recent Developments and Current OpportunitiesStephen Fowler, Peter N Morcos, Yumi Cleary, et al.Clinical Pharmacology and Therapeutics|December 12, 2017
Model-Based Assessments of CYP-Mediated Drug-Drug Interaction Risk of Alectinib: Physiologically Based Pharmacokinetic Modeling Supported Clinical DevelopmentYumi Cleary, Michael Gertz, Peter N Morcos, et al.Clinical Pharmacology and Therapeutics|August 4, 2021
Model-Based Drug-Drug Interaction Extrapolation Strategy From Adults to Children: Risdiplam in Pediatric Patients With Spinal Muscular AtrophyYumi Cleary, Michael Gertz, Paul Grimsey, et al.European Journal of Clinical Pharmacology|March 25, 2015
Evaluating a physiologically based pharmacokinetic model for prediction of omeprazole clearance and assessing ethnic sensitivity in CYP2C19 metabolic pathwaySheng Feng, Yumi Cleary, Neil Parrott, et al.Journal of Clinical Pharmacology|July 28, 2018
Effect of Hepatic Impairment on the Pharmacokinetics of AlectinibPeter N Morcos, Yumi Cleary, Carolina Sturm-Pellanda, et al.Pageof 2